HK1036019A1 - Treatment of cardiac hypertrophy. - Google Patents

Treatment of cardiac hypertrophy.

Info

Publication number
HK1036019A1
HK1036019A1 HK01107048A HK01107048A HK1036019A1 HK 1036019 A1 HK1036019 A1 HK 1036019A1 HK 01107048 A HK01107048 A HK 01107048A HK 01107048 A HK01107048 A HK 01107048A HK 1036019 A1 HK1036019 A1 HK 1036019A1
Authority
HK
Hong Kong
Prior art keywords
treatment
cardiac hypertrophy
hypertrophy
cardiac
Prior art date
Application number
HK01107048A
Other languages
English (en)
Inventor
Hongkui Jin
Hsienwie Lu
Nicholas J Paoni
Renhui Yang
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of HK1036019A1 publication Critical patent/HK1036019A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
HK01107048A 1998-04-02 2001-10-08 Treatment of cardiac hypertrophy. HK1036019A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8044898P 1998-04-02 1998-04-02
PCT/US1999/006032 WO1999051260A2 (fr) 1998-04-02 1999-03-19 Traitement de l'hypertrohie cardiaque

Publications (1)

Publication Number Publication Date
HK1036019A1 true HK1036019A1 (en) 2001-12-21

Family

ID=22157456

Family Applications (2)

Application Number Title Priority Date Filing Date
HK01107048A HK1036019A1 (en) 1998-04-02 2001-10-08 Treatment of cardiac hypertrophy.
HK07102777.8A HK1099197A1 (en) 1998-04-02 2007-03-15 Use of interferon gamma for the treatment of cardiac hypertrophy

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK07102777.8A HK1099197A1 (en) 1998-04-02 2007-03-15 Use of interferon gamma for the treatment of cardiac hypertrophy

Country Status (18)

Country Link
US (2) US6187304B1 (fr)
EP (2) EP1702623B1 (fr)
JP (2) JP5030329B2 (fr)
CN (1) CN1201814C (fr)
AR (1) AR018174A1 (fr)
AT (2) ATE410181T1 (fr)
AU (1) AU757910B2 (fr)
BR (1) BR9909422A (fr)
CA (1) CA2325442C (fr)
DE (2) DE69932235T2 (fr)
DK (2) DK1702623T3 (fr)
ES (2) ES2314786T3 (fr)
HK (2) HK1036019A1 (fr)
IL (1) IL138812A0 (fr)
NZ (1) NZ506854A (fr)
TW (1) TWI243682B (fr)
WO (1) WO1999051260A2 (fr)
ZA (1) ZA200004854B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020192659A1 (en) * 1997-09-17 2002-12-19 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU757910B2 (en) * 1998-04-02 2003-03-13 Genentech Inc. Treatment of cardiac hypertrophy
IL147442A0 (en) * 1999-07-12 2002-08-14 Genentech Inc Promotion or inhibition of angiogenesis and cardiovscularization by tumor necrosis factor ligand/receptor homologs
US7838225B2 (en) * 1999-10-29 2010-11-23 Hologic, Inc. Methods for detection of a target nucleic acid by forming a cleavage structure using a reverse transcriptase
US8110218B2 (en) * 2000-11-30 2012-02-07 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic protein-lipid complexes
US7625584B2 (en) * 2000-11-30 2009-12-01 The Research Foundation Of State University Of New York Method of complexing a protein by the use of a dispersed system and proteins thereof
AU2002310922A1 (en) * 2001-05-04 2002-11-18 Institute Of Molecular And Cell Biology Interferons in the treatment of ischemia
AU2002342163B2 (en) * 2001-11-06 2007-11-08 Laboratoires Serono Sa Methods of treating endometreosis
EP3192528A1 (fr) * 2002-02-14 2017-07-19 Chugai Seiyaku Kabushiki Kaisha Formulation des solutions contenant des anti-corps anti-il-6r comportant un sucre comme stabilisateur
AU2003257588A1 (en) * 2002-08-29 2004-03-19 Santen Pharmaceutical Co., Ltd. REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND PROSTAGLANDINS
WO2004045644A1 (fr) * 2002-11-18 2004-06-03 Santen Pharmaceutical Co., Ltd. Medicament contre le glaucome comprenant un inhibiteur de la rho-kinase et un betabloquant
EP1522857A1 (fr) * 2003-10-09 2005-04-13 Universiteit Maastricht Méthode pour identifier des individus qui risquent de développer une défaillance cardiaque par la détection du taux de galectine-3 ou thrombospondine-2
WO2009154770A2 (fr) * 2008-06-18 2009-12-23 The Texas A & M University System Cellules souches mésenchymateuses, compositions et procédés pour le traitement des lésions du tissu cardiaque

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU561343B2 (en) 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
US5582824A (en) 1981-10-19 1996-12-10 Genentech, Inc. Recombinant DES-CYS-TYR-CYS human immune interferon
US5096705A (en) 1981-10-19 1992-03-17 Genentech, Inc. Human immune interferon
US4929544A (en) 1982-04-23 1990-05-29 Sri International Reagents, methods, and test kit for diagnosing/monitoring cancer in humans
US4855238A (en) 1983-12-16 1989-08-08 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
US4944941A (en) 1987-08-07 1990-07-31 Genentech, Inc. Methods and compositions for the treatment of lung conditions
US5151265A (en) * 1987-11-03 1992-09-29 Genentech, Inc. Gamma interferon formulation
IL88233A (en) * 1987-11-03 1993-08-18 Genentech Inc Gamma interferon formulation
SE462364B (sv) 1988-09-30 1990-06-18 Goeran Hansson Anvaendning av gamma-interferon foer beredning av ett preparat foer behandling av vaskulaer stenos
DK0502997T3 (da) 1989-12-01 1995-07-17 Childrens Medical Center Behandling af atopiske sygdomme med gamma-interferon
US6207641B1 (en) * 1995-03-10 2001-03-27 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Pharmaceutical composition containing IFN-γ inducing polypeptide or factor for treating and/or preventing IFN-γ susceptive diseases
US5573762A (en) 1995-04-24 1996-11-12 Genentech, Inc. Use of leukemia inhibitory factor specific antibodies and endothelin antagonists for treatment of cardiac hypertrophy
CA2203377A1 (fr) * 1995-08-30 1997-03-06 Akira Matsumori Methode d'analyse de la myocartdite ou de la cardiomyopathie
AU757910B2 (en) * 1998-04-02 2003-03-13 Genentech Inc. Treatment of cardiac hypertrophy

Also Published As

Publication number Publication date
IL138812A0 (en) 2001-10-31
ATE410181T1 (de) 2008-10-15
DE69932235D1 (de) 2006-08-17
EP1067958A2 (fr) 2001-01-17
AR018174A1 (es) 2001-10-31
EP1702623A3 (fr) 2007-01-10
HK1099197A1 (en) 2007-08-10
JP2002510645A (ja) 2002-04-09
US6187304B1 (en) 2001-02-13
CA2325442C (fr) 2011-10-11
WO1999051260A3 (fr) 1999-12-09
JP2009256375A (ja) 2009-11-05
CA2325442A1 (fr) 1999-10-14
EP1702623B1 (fr) 2008-10-08
EP1702623A2 (fr) 2006-09-20
CN1300221A (zh) 2001-06-20
DE69932235T2 (de) 2007-06-14
NZ506854A (en) 2003-07-25
ES2267258T3 (es) 2007-03-01
AU3102499A (en) 1999-10-25
CN1201814C (zh) 2005-05-18
BR9909422A (pt) 2001-09-11
ES2314786T3 (es) 2009-03-16
DE69939723D1 (de) 2008-11-20
ZA200004854B (en) 2001-09-26
WO1999051260A2 (fr) 1999-10-14
EP1067958B1 (fr) 2006-07-05
DK1702623T3 (da) 2009-01-19
JP5030329B2 (ja) 2012-09-19
AU757910B2 (en) 2003-03-13
US6989364B1 (en) 2006-01-24
TWI243682B (en) 2005-11-21
ATE332144T1 (de) 2006-07-15
DK1067958T3 (da) 2006-11-06

Similar Documents

Publication Publication Date Title
AU2001249881A1 (en) Method of treating the heart
GB9824436D0 (en) Methods of treatment
ZA200108446B (en) Novel method of treatment.
HK1099197A1 (en) Use of interferon gamma for the treatment of cardiac hypertrophy
ZA991220B (en) Method of treating heart failure.
GB9800942D0 (en) Well treatment
ZA986363B (en) Novel method of treatment.
ZA97986B (en) Treatment of liquors.
ZA985237B (en) Novel method of treatment.
AU8451298A (en) Treatment of fabrics
GB2339576B (en) Biomass treatment
ZA986364B (en) Novel method of treatment.
ZA986365B (en) Novel method of treatment.
ZA99253B (en) Treatment of waxes.
ZA973380B (en) Treatment of washwater.
ZA200109120B (en) Use of Arylalkanoylpyridazines.
ZA200007396B (en) Method of treatment.
AP2005003432A0 (en) Novel method of treatment.
AU6088099A (en) Water treatment
ZA994585B (en) Treatment of water.
GB9818524D0 (en) Inorgasmia treatment
GB9815497D0 (en) Treatment
ZA996625B (en) Treatment of congestive heart failure.
ZA996546B (en) Treatment of water.
ZA994584B (en) Treatment of water.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20140319